jeudi 16 avril 2020

Onco Actu du 16 avril 2020


1.1 BIOLOGIE - GÉNOME



Massive study reveals how “hypermutated” malignant brain tumors with many mutations escape chemotherapy and immunotherapy [Dana-Farber Cancer Institute]











3.4.1 CHIMIOPRÉVENTION - ASPIRINE



Aspirin linked to reduction in risk of several cancers of the digestive tract [ESMO]










4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



QIAGEN launches therascreen BRAF test as companion diagnostic to a BRAFTOVI® (encorafenib) based regimen in metastatic colorectal cancer [Qiagen]











5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS



Gilead in talks about buying stake in TIGIT biotech Arcus: report [Fierce Biotech]











Is Gilead chief Dan O’Day ready for a new biotech deal in the oncology field? [EndPoints]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



International Task Force Provides Emergency Guidance for Radiation Therapy to Continue Treating Patients with Hematologic Malignancies During Pandemic [ASH]










5.2 PHARMA



Merck, Samsung join newly crowded market for Herceptin biosimilars [Biopharma Dive]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug [Xconomy]











UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer [UroGen]











FDA Approves First Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer [FDA]